More study needed into the ‘why’ of new weight-loss drugs
University of Washington School of MedicineThese drugs are not the be-all and end-all to weight-loss therapy, wrote Dr. Michael Schwartz in a commentary published Oct. 2 in The Journal of Clinical Investigation. His co-author was Sophie Yang Gou, a postdoctoral fellow in Schwartz’s lab at the University of Washington School of Medicine. Many experts seem to be saying “OK, we’ve fixed this problem. We’re done,” noted Schwartz, who co-directs the UW Medicine Diabetes Institute. That is simply not the case, he said.